<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Type I interferons for induction of remission in ulcerative colitis - Wang, Y - 2015 | Cochrane Library</title> <meta content="Type I interferons for induction of remission in ulcerative colitis - Wang, Y - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006790.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Type I interferons for induction of remission in ulcerative colitis - Wang, Y - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006790.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006790.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Type I interferons for induction of remission in ulcerative colitis" name="citation_title"/> <meta content="Yongjun Wang" name="citation_author"/> <meta content="Robarts Research Institute" name="citation_author_institution"/> <meta content="John K MacDonald" name="citation_author"/> <meta content="Robarts Research Institute" name="citation_author_institution"/> <meta content="Eric I Benchimol" name="citation_author"/> <meta content="The Children's Hospital of Eastern Ontario" name="citation_author_institution"/> <meta content="Anne Marie Griffiths" name="citation_author"/> <meta content="The Hospital for Sick Children" name="citation_author_institution"/> <meta content="A Hillary Steinhart" name="citation_author"/> <meta content="Mount Sinai Hospital" name="citation_author_institution"/> <meta content="Remo Panaccione" name="citation_author"/> <meta content="University Of Calgary" name="citation_author_institution"/> <meta content="Cynthia H Seow" name="citation_author"/> <meta content="University of Calgary" name="citation_author_institution"/> <meta content="cseow@ucalgary.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD006790.pub3" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/09/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006790.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006790.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006790.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Inflammatory Agents [therapeutic use]; Colitis, Ulcerative [*drug therapy]; Enema [methods]; Induction Chemotherapy; Interferon Type I [*therapeutic use]; Interferon‐alpha [therapeutic use]; Interferon‐beta [therapeutic use]; Prednisolone [therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006790.pub3&amp;doi=10.1002/14651858.CD006790.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="7LavyS58";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006790\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006790\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006790.pub3",title:"Type I interferons for induction of remission in ulcerative colitis",firstPublishedDate:"Sep 14, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7LavyS58&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006790.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006790.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006790.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006790.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006790.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006790.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006790.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006790.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006790.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006790.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>882 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006790.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full#CD006790-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full#CD006790-sec-0031"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full#CD006790-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full#CD006790-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full#CD006790-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full#CD006790-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full#CD006790-sec-0026"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full#CD006790-sec-0030"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/appendices#CD006790-sec-0036"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/table_n/CD006790StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/table_n/CD006790StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Type I interferons for induction of remission in ulcerative colitis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/information#CD006790-cr-0002">Yongjun Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/information#CD006790-cr-0003">John K MacDonald</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/information#CD006790-cr-0004">Eric I Benchimol</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/information#CD006790-cr-0005">Anne Marie Griffiths</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/information#CD006790-cr-0006">A Hillary Steinhart</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/information#CD006790-cr-0007">Remo Panaccione</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006790.pub3/information#CD006790-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Cynthia H Seow</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/information/en#CD006790-sec-0041">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 September 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006790.pub3">https://doi.org/10.1002/14651858.CD006790.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006790-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006790-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006790-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006790-abs-0005">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006790-abs-0001" lang="en"> <section id="CD006790-sec-0001"> <h3 class="title" id="CD006790-sec-0001">Background</h3> <p>Interferons (IFNs) are cytokines which possess immunoregulatory properties and have been used to successfully treat a number of chronic inflammatory disorders. It has been postulated that Type I IFNs may be able to re‐establish the Th1/Th2 balance in Th2 predominant diseases like ulcerative colitis. </p> </section> <section id="CD006790-sec-0002"> <h3 class="title" id="CD006790-sec-0002">Objectives</h3> <p>To systematically evaluate the efficacy and safety of type I IFN therapy for induction of remission in ulcerative colitis. </p> </section> <section id="CD006790-sec-0003"> <h3 class="title" id="CD006790-sec-0003">Search methods</h3> <p>We searched MEDLINE, EMBASE, CENTRAL, the Cochrane IBD/FBD group specialised register, and ClinicalTrials.gov from inception to August 8, 2014. Reference lists of trials and review articles, as well as recent proceedings from major gastroenterology meetings were manually searched. </p> </section> <section id="CD006790-sec-0004"> <h3 class="title" id="CD006790-sec-0004">Selection criteria</h3> <p>Randomised controlled trials of type I IFNs for induction of remission in UC were included. The study population included patients of any age with active ulcerative colitis. There were no exclusions based on type, dose or duration of IFN treatment. </p> </section> <section id="CD006790-sec-0005"> <h3 class="title" id="CD006790-sec-0005">Data collection and analysis</h3> <p>Two independent authors reviewed studies for eligibility, extracted the data and assessed study quality using the Cochrane risk of bias tool. The overall quality of the evidence supporting the outcomes was evaluated using the GRADE criteria. The primary outcome was induction of remission of ulcerative colitis. Secondary outcomes included: time to remission, mean change in disease activity index score, clinical, histological or endoscopic improvement, improvement in quality of life, and adverse events. We calculated the risk ratio (RR) and corresponding 95% confidence interval (CI) for dichotomous outcomes. We calculated the mean difference and corresponding 95% confidence interval for continuous outcomes. Meta‐analysis was performed using RevMan 5.3.5 software. </p> </section> <section id="CD006790-sec-0006"> <h3 class="title" id="CD006790-sec-0006">Main results</h3> <p>Six studies were eligible for inclusion (517 patients). Five studies compared type I IFNs to placebo injections (485 patients) and a single study compared IFNs to prednisolone enemas in patients with left‐sided colitis (32 patients). The active comparator study was rated as high risk of bias due to an open‐label design. Three studies were rated as unclear risk of bias for random sequence generation and allocation concealment. Two studies described as double blind were rated as unclear risk of bias for blinding. There was no significant benefit of type I IFNs over placebo for inducing clinical remission or improvement in patients with active ulcerative colitis. Thirty‐six per cent (87/242) of patients in the type I IFNs group achieved clinical remission by 8 to 12 weeks compared to 30% (36/120) of placebo patients (RR 1.16, 95% CI 0.84 to 1.58; 4 studies, 362 patients). A GRADE analysis indicated that the overall quality of the evidence supporting the outcome clinical remission was moderate due to sparse data (123 events). Fifty‐six per cent (149/264) of patients in the type I IFNs group improved clinically by 8 to 12 weeks compared to 48% (77/161) of placebo patients (RR 1.16, 95% CI 0.96 to 1.40; 4 studies, 425 patients). A GRADE analysis indicated that the overall quality of the evidence supporting the outcome clinical improvement was moderate due to sparse data (226 events). Patients who received type I IFNs were significantly more likely to withdraw from the studies due to adverse events than those who received placebo. Seven per cent (18/42) of type I IFNs patients withdrew due to adverse events compared to 2% (3/152) of placebo patients (RR 3.16, 95% CI 1.06 to 9.40). A GRADE analysis indicated that the overall quality of the evidence supporting the outcome withdrawal due to adverse events was low due to very sparse data (21 events). The study comparing type I IFNs to prednisolone enemas found no difference between the treatment groups in quality of life or disease activity scores. Common adverse events included headaches, arthralgias, myalgias, fatigue, back pain, nausea, application site reactions, rigors, and fevers. There were no statistically significant differences in the other secondary outcomes. </p> </section> <section id="CD006790-sec-0007"> <h3 class="title" id="CD006790-sec-0007">Authors' conclusions</h3> <p>Moderate quality evidence suggests that type I IFNs are not effective for the induction of remission in UC. In addition, there are concerns regarding the tolerability of this class of treatment. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006790-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006790-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006790-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006790-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006790-abs-0002" lang="en"> <h3>Type I interferons for treatment of active ulcerative colitis</h3> <p><b>What is ulcerative colitis?</b> </p> <p>Ulcerative colitis (UC) is a long‐term (chronic) inflammatory bowel disease characterized by abdominal pain, bloody diarrhea, and a need to hurry to the toilet to pass feces (fecal urgency). </p> <p><b>What are type I interferons?</b> </p> <p>Interferons (IFNs) are drugs that regulate the immune system and have been used to successfully treat a number of chronic inflammatory disorders. People with UC who are experiencing disease symptoms have ‘active’ disease, periods when the symptoms stop are called ‘remission’. </p> <p><b>What did the researchers investigate?</b> </p> <p>The researchers investigated whether type I IFNs results in remission in people with active ulcerative colitis, and whether it causes any harms (side effects). The researchers searched the medical literature extensively up to August 8, 2014. </p> <p><b>What did the researchers find?</b> </p> <p>The researchers identified six studies that included a total of 517 participants. Five studies (total 485 participants) compared type I IFNs to placebo (fake medicine) injections. One small (32 participants) low quality study compared types I IFNs to prednisolone (a steroid drug) enemas. This study did not measure remission and found no difference between the treatment groups in quality of life or disease activity scores. There was no difference between type I interferons and placebo treatment groups for the number of people who achieved remission or improvement of their symptoms. These results suggest that type I IFNs do not produce remission from ulcerative colitis. Common side effects included headaches, arthralgias (joint pain), myalgias (muscle pain), fatigue, back pain, nausea, injection site reactions, rigors (cold and shivering), and fevers. </p> <p>At present, the results from medical trials do not support the use of type I IFNs for the production of remission in active ulcerative colitis. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006790-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006790-sec-0031"></div> <h3 class="title" id="CD006790-sec-0032">Implications for practice</h3> <section id="CD006790-sec-0032"> <p>Moderate quality evidence suggests that type I IFNs are not effective for induction of remission in UC. Furthermore, there are concerns regarding the tolerability of this class of treatment. </p> </section> <h3 class="title" id="CD006790-sec-0033">Implications for research</h3> <section id="CD006790-sec-0033"> <p>Several well‐designed studies that were included in this review, did not demonstrate any benefit for type I IFNs therapy in patients with ulcerative colitis. Further research is unlikely to yield any drastically different results. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006790-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006790-sec-0015"></div> <div class="table" id="CD006790-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Type I Interferons compared to placebo for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Type I Interferons compared to placebo for induction of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with induction of remission in ulcerative colitis<br/> <b>Settings:</b> Outpatient<br/> <b>Intervention:</b> Type I Interferons<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Type I Interferons</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Remission</b> <br/> Follow‐up: 8‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b> <br/> (252 to 474) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b> <br/> (0.84 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>362<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical improvement</b> <br/> Follow‐up: 8‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>478 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>554 per 1000</b> <br/> (459 to 669) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.16</b> <br/> (0.96 to 1.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>425<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> <br/> Follow‐up: 8‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>46 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>34 per 1000</b> <br/> (6 to 190) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.74</b> <br/> (0.13 to 4.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>468<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> <br/> Follow‐up: 8‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>20 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>62 per 1000</b> <br/> (21 to 186) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.16</b> <br/> (1.06 to 9.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>394<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk comes from control arm of study<br/> <sup>2</sup> Downgraded one level due to sparse data (123 events)<br/> <sup>3</sup> Dowgraded one level due to sparse data (226 events)<br/> <sup>4</sup> Downgraded two levels due to very sparse data (20 events)<br/> <sup>5</sup> Downgraded two levels due to very sparse data (21 events) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006790-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006790-sec-0016"></div> <p><b>Ulcerative colitis</b><br/> Ulcerative colitis (UC) is characterized by chronic or recurrent contiguous inflammation of the colonic mucosa resulting in symptoms such as bloody diarrhoea, abdominal discomfort, urgency and tenesmus. Inflammation typically arises in the distal colon and extends in a proximal direction. The disease can be subcategorised by anatomic extent. Left sided colitis is defined by inflammation that does not extend beyond the splenic flexure, and pancolitis where there is more proximal involvement. UC varies in severity and patients often experience cycles of relapses and remissions. While the exact cause of the disorder remains to be determined, environmental factors are thought to modify disease presentation in genetically predisposed individuals (<a href="./references#CD006790-bbs2-0025" title="EkWE , D'AmatoM , HalfvarsonJ . The history of genetics in inflammatory bowel disease. Annals of Gastroenterology2014;27(4):294‐303. ">Ek 2014</a>; <a href="./references#CD006790-bbs2-0036" title="HansenR , ThomsonJM , El‐OmarEM , HoldGL . The role of infection in the aetiology of inflammatory bowel disease. Journal of Gastroenterology2010;45(3):266‐76. ">Hansen 2010</a>; <a href="./references#CD006790-bbs2-0044" title="KoY , ButcherR , LeongRW . Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseases. World Journal of Gastroenterology2014;20(5):1238‐47. ">Ko 2014</a>; <a href="./references#CD006790-bbs2-0068" title="ZhangYZ , LiYY . Inflammatory bowel disease: pathogenesis. World Journal of Gastroenterology2014;20(1):91‐9. ">Zhang 2014</a>; <a href="./references#CD006790-bbs2-0035" title="HanauerSB . Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflammatory Bowel Diseases2006;12 Suppl 1:S3‐9. ">Hanauer 2006</a>). From an immunological perspective, the naive T cells (Th0) preferentially differentiate into Th2 (T‐helper) lymphocytes, which express a predominant interleukin‐4 (IL‐4), IL‐5, IL‐13 cytokine profile (<a href="./references#CD006790-bbs2-0030" title="GeremiaA , BiancheriP , AllanP , CorazzaGR , DiSabatinoA . Innate and adaptive immunity in inflammatory bowel disease. Autoimmunity Reviews2014;13(1):3‐10. ">Geremia 2014</a>; <a href="./references#CD006790-bbs2-0021" title="BoumaG , StroberW . The immunological and genetic basis of inflammatory bowel disease. Nature reviews. Immunology2003;3(7):521‐33. ">Bouma 2003</a>). However, UC represents an 'atypical' Th2 disease as increased circulating levels of interferon‐γ and TNF‐α (tumour necrosis factor‐α) have also been identified (<a href="./references#CD006790-bbs2-0064" title="TsukadaY , NakamuraT , IimuraM , IizukaBE , HayashiN . Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. American Journal of Gastroenterology2002;97(11):2820‐8. ">Tsukada 2002</a>; <a href="./references#CD006790-bbs2-0037" title="HellerF , FlorianP , BojarskiC , RichterJ , ChristM , HillenbrandB , et al. Interleukin‐13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology2005;129(2):550‐64. ">Heller 2005</a>; <a href="./references#CD006790-bbs2-0042" title="JovanovicK , SiebeckM , GroppR . The route to pathologies in chronic inflammatory diseases characterized by T helper type 2 immune cells. Clinical and Experimental Immunology2014;178(2):201‐11. ">Jovanovic 2014</a>). It is hypothesized that this imbalance in circulating pro‐inflammatory and anti‐inflammatory cytokines underlies the chronic disease state (<a href="./references#CD006790-bbs2-0030" title="GeremiaA , BiancheriP , AllanP , CorazzaGR , DiSabatinoA . Innate and adaptive immunity in inflammatory bowel disease. Autoimmunity Reviews2014;13(1):3‐10. ">Geremia 2014</a>; <a href="./references#CD006790-bbs2-0017" title="BaumgartDC , CardingSR . Inflammatory bowel disease: cause and immunobiology. Lancet2007;369(9573):1627‐40. ">Baumgart 2007</a>).<br/> <br/> The mainstay of UC treatment comprises anti‐inflammatory agents in the form of 5‐aminosalicylic acid compounds (<a href="./references#CD006790-bbs2-0061" title="TravisSP . Review article: induction therapy for patients with active ulcerative colitis. Alimentary Pharmacology and Therapeutics2006;24 Suppl 1:10‐6. ">Travis 2006</a>), glucocorticoids (<a href="./references#CD006790-bbs2-0063" title="TrueloveSC , WittsLJ . Cortisone in ulcerative colitis; final report on a therapeutic trial. British Medical Journal1955;2(4947):1041‐8. ">Truelove 1955</a>), immunosuppressives (<a href="./references#CD006790-bbs2-0060" title="TimmerA , McDonaldJWD , TsoulisDJ , MacDonaldJK . Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD000478.pub3] ">Timmer 2012</a>), and more recently monoclonal antibodies against tumour necrosis factor‐alpha (TNF‐ɑ) (<a href="./references#CD006790-bbs2-0052" title="RutgeertsP , SandbornWJ , FeaganBG , ReinischW , OlsonA , JohannsJ , et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2005;353(23):2462‐76. ">Rutgeerts 2005</a>) and integrin ɑ4ß7 (<a href="./references#CD006790-bbs2-0026" title="FeaganBG , RutgeertsP , SandsBE , HanauerS , ColombelJF , SandbornWJ , et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine2013;369(8):699‐710. ">Feagan 2013</a>). These standard medical therapeutic options vary in efficacy, and importantly, toxicity (<a href="./references#CD006790-bbs2-0019" title="BernsteinCN . Treatment of IBD: where we are and where we are going. American Journal of Gastroenterology2015;110(1):114‐26. ">Bernstein 2015</a>). While surgery may be considered 'curative' by some, this is often not ideal, rendering some patients with permanent ostomies and others with ongoing symptomatology, including that associated with suboptimal ileoanal pouch function. Therefore, alternative treatments are continually being evaluated. </p> <p><b>Interferons</b><br/> Interferons (IFNs) are cytokines which may be released in response to viruses, bacteria, parasites and tumour cells. Interferons possess immunoregulatory, antiviral and anti‐cancer properties (<a href="./references#CD006790-bbs2-0029" title="GeorgePM , BadigerR , AlazawiW , FosterGR , MitchellJA . Pharmacology and therapeutic potential of interferons. Pharmacology &amp; Therapeutics2012;135(1):44‐53. ">George 2012</a>). IFNs have been used to successfully treat a number of chronic inflammatory disorders including multiple sclerosis (<a href="./references#CD006790-bbs2-0043" title="KasperLH , RederAT . Immunomodulatory activity of interferon‐beta. Annals of Clinical and Translational Neurology2014;1(8):622‐31. ">Kasper 2014</a>; <a href="./references#CD006790-bbs2-0014" title="Anonymous . Randomised double‐blind placebo‐controlled study of interferon beta‐1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta‐1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet1998;352(9139):1498‐504. ">Anonymous 1998</a>; <a href="./references#CD006790-bbs2-0015" title="Anonymous . PRISMS‐4: Long‐term efficacy of interferon‐beta‐1a in relapsing MS. Neurology2001;56(12):1628‐36. ">Anonymous 2001</a>), and chronic viral hepatitis (<a href="./references#CD006790-bbs2-0045" title="KoretzRL , PleguezueloM , ArvanitiV , Barrera BaenaP , CiriaR , GurusamyKS , et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD003617.pub2] ">Koretz 2013</a>; <a href="./references#CD006790-bbs2-0040" title="HoofnagleJH , SeeffLB . Peginterferon and ribavirin for chronic hepatitis C. New England Journal of Medicine2006;355(23):2444‐51. ">Hoofnagle 2006</a>). There are two main classes of IFNs: type I IFNs (which include α, β, ε, Ω, κ isoforms) (<a href="./references#CD006790-bbs2-0041" title="IvashkivLB , DonlinLT . Regulation of type I interferon responses. Nature reviews. Immunology2014;14(1):36‐49. ">Ivashkiv 2014</a>; <a href="./references#CD006790-bbs2-0047" title="LudigsK , ParfenovV , Du PasquierRA , GuardaG . Type I IFN‐mediated regulation of IL‐1 production in inflammatory disorders. Cellular and Molecular Life Sciences2012;69(20):3395‐418. ">Ludigs 2012</a>), and type II IFNs (γ isoform) (<a href="./references#CD006790-bbs2-0031" title="GhoshS , ChaudharyR , CarpaniM , PlayfordR . Interfering with interferons in inflammatory bowel disease. Gut2006;55(8):1071‐73. ">Ghosh 2006</a>). More recently a new family of antiviral cytokines, the type III IFNs (λ isoform) has been identified (<a href="./references#CD006790-bbs2-0023" title="DurbinRK , KotenkoSV , DurbinJE . Interferon induction and function at the mucosal surface. Immunological Reviews2013;255(1):25‐39. ">Durbin 2013</a>). </p> <p>This systematic review will focus on the use of type I IFNs for the induction of remission of UC, specifically IFN‐α and IFN‐β which are marketed in standard recombinant or pegylated forms. IFN‐α has been shown to enhance human Th1 responses. This helps to re‐establish the Th1/Th2 balance in Th2 predominant diseases by down‐regulating Th2 cytokines such as IL‐4, IL‐5 and IL‐13 (<a href="./references#CD006790-bbs2-0056" title="ShibuyaH , HirohataS . Differential effects of IFN‐alpha on the expression of various TH2 cytokines in human CD4+ T cells. Journal of Allergy and Clinical Immunology2005;116(1):205‐12. ">Shibuya 2005</a>; <a href="./references#CD006790-bbs2-0022" title="BrassardDL , GraceMJ , BordensRW . Interferon‐alpha as an immunotherapeutic protein. Journal of Leukocyte Biology2002;71(4):565‐81. ">Brassard 2002</a>). IFN‐β increases the expression of anti‐inflammatory IL‐10, inhibits IFN‐γ, TNF‐α, and enhances regulatory T lymphocyte and NK (natural killer) cell activity (<a href="./references#CD006790-bbs2-0032" title="GraberJJ , FordD , ZhanM , FrancisG , PanitchH , Dhib‐JalbutS . Cytokine changes during interferon‐beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. Journal of Neuroimmunology2007;185(1‐2):168‐74. ">Graber 2007</a>). As IFN‐α and IFN‐β share a cellular surface receptor, they both induce IL‐1Ra. </p> <p>Initial interest in IFNs for UC arose from an incidental observation of a patient with known UC who experienced a dramatic improvement in his UC symptoms when he was treated with IFN‐α2a for concurrent chronic hepatitis B (<a href="./references#CD006790-bbs2-0013" title="SümerN , PalabiyikoğluM . Induction of remission by interferon‐alpha in patients with chronic active ulcerative colitis. European Journal of Gastroenterology and Hepatology1995;7(7):597‐602. ">Sümer 1995</a>). This led to a small prospective open‐label study by the same investigators in which 28 inpatients who had failed to respond to 5‐aminosalicylic acid compounds and oral or topical corticosteroids were treated with IFN‐α2a therapy for 6 to 12 months. Eighty‐two percent of patients responded to therapy within 15 days and were in complete clinical endoscopic remission after 6 months of therapy (<a href="./references#CD006790-bbs2-0013" title="SümerN , PalabiyikoğluM . Induction of remission by interferon‐alpha in patients with chronic active ulcerative colitis. European Journal of Gastroenterology and Hepatology1995;7(7):597‐602. ">Sümer 1995</a>). Subsequently, <a href="./references#CD006790-bbs2-0011" title="MuschE , AndusT , MalekM . Induction and maintenance of clinical remission by interferon‐beta in patients with steroid‐refractory active ulcerative colitis ‐ an open long‐term pilot trial. Alimentary Pharmacology and Therapeutics2002;16(7):1233‐9. ">Musch 2002</a> trialed IFN‐β‐1a in 25 steroid refractory UC patients in an open label study. The decision to use IFN‐β rather than IFN‐α occurred in response to its clinical utility in the chronic inflammatory disorder, multiple sclerosis. Furthermore, in vitro studies had suggested that IFN‐β, in contrast to IFN‐α or IFN‐γ did not enhance the production of inflammatory metabolites of arachidonic acid or leukotriene B4. A total of 88% of patients entered remission with a mean time to response of 21 days (<a href="./references#CD006790-bbs2-0011" title="MuschE , AndusT , MalekM . Induction and maintenance of clinical remission by interferon‐beta in patients with steroid‐refractory active ulcerative colitis ‐ an open long‐term pilot trial. Alimentary Pharmacology and Therapeutics2002;16(7):1233‐9. ">Musch 2002</a>). </p> <p>The adverse effect profile of IFNs includes flu‐like symptoms including fever, headache, malaise, alopecia and arthralgias. Other potential adverse events include skin rashes, psychological disturbances, and perturbations in the haematological profile. IFNs may also induce autoimmune complications including thyroid disorders, diabetes mellitus and alopecia (<a href="./references#CD006790-bbs2-0020" title="BorgFA , IsenbergDA . Syndromes and complications of interferon therapy. Current Opinion in Rheumatology2007;19(1):61‐6. ">Borg 2007</a>; <a href="./references#CD006790-bbs2-0049" title="OkanoueT , SakamotoS , ItohY , MinamiM , YasuiK , SakamotoM , et al. Side effects of high‐dose interferon therapy for chronic hepatitis C. Journal of Hepatology1996;25(3):283‐91. ">Okanoue 1996</a>). Of concern, there have been isolated case reports documenting the association between IFNs and the induction of ischaemic colitis (<a href="./references#CD006790-bbs2-0049" title="OkanoueT , SakamotoS , ItohY , MinamiM , YasuiK , SakamotoM , et al. Side effects of high‐dose interferon therapy for chronic hepatitis C. Journal of Hepatology1996;25(3):283‐91. ">Okanoue 1996</a>; <a href="./references#CD006790-bbs2-0057" title="SparanoJA , DutcherJP , KaleyaR , CaliendoG , FioritoJ , MitsudoS , et al. Colonic ischemia complicating immunotherapy with interleukin‐2 and interferon‐alpha. Cancer1991;68(7):1538‐44. ">Sparano 1991</a>; <a href="./references#CD006790-bbs2-0059" title="TadaH , SaitohS , NakagawaY , HiranaH , MorimotoM , ShimaT , et al. Ischemic colitis during interferon‐alpha treatment for chronic active hepatitis C. Journal of Gastroenterology1996;31(4):582‐4. ">Tada 1996</a>), and ulcerative colitis (<a href="./references#CD006790-bbs2-0065" title="TursiA . Rapid onset of ulcerative colitis after treatment with PEG‐interferon plus ribavirin for chronic hepatitis C. Inflammatory Bowel Diseases2007;13(9):1189‐90. ">Tursi 2007</a>; <a href="./references#CD006790-bbs2-0067" title="WatanabeT , InoueM , HaradaK , HommaN , UchidaM , OgataN , et al. A case of exacerbation of ulcerative colitis induced by combination therapy with PEG‐interferon alpha‐2b and ribavirin. Gut2006;55(11):1682‐3. ">Watanabe 2006</a>; <a href="./references#CD006790-bbs2-0058" title="SprengerR , SagmeisterM , OffnerF . Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis. Gut2005;54(3):438‐9. ">Sprenger 2005</a>; <a href="./references#CD006790-bbs2-0048" title="MavrogiannisC , PapanikolaouIS , ElefsiniotisIS , PsilopoulosDI , KaramerisA , KarvountzisG . Ulcerative colitis associated with interferon treatment for chronic hepatitis C. Journal of Hepatology2001;34(6):964‐5. ">Mavrogiannis 2001</a>). In contrast, <a href="./references#CD006790-bbs2-0007" title="BargiggiaS , ThorburnD , AnderloniA , ArdizzoneS , GiorgiA , PorroGB , et al. Is interferon‐alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case‐control study. Alimentary Pharmacology and Therapeutics2005;22(3):209‐15. ">Bargiggia 2005</a> conducted a case control study of IFN‐α therapy in patients with concomitant inflammatory bowel disease and chronic active hepatitis C and determined that no patients developed an IBD relapse during IFN treatment or in the following 12 month follow‐up. Therefore, there is a need to critically evaluate if IFN therapy results in improvement or detriment to patients with UC. </p> <p>Commercially available type I IFNs have different pharmacokinetic profiles, and consequently there is variation in the frequency and mode of administration. IFNs can be administered on alternate days, thrice weekly, or once a week by subcutaneous or intramuscular injection. Some of the IFNs are available in pegylated forms to reduce clearance. Pegylation is the process by which the biologically inert polyethylene glycol chains are cross linked to the active moiety, in this case the IFN protein, to optimise overall pharmacokinetics (<a href="./references#CD006790-bbs2-0028" title="FosterGR . Review article: pegylated interferons: chemical and clinical differences. Alimentary Pharmacology and Therapeutics2004;20(8):825‐30. ">Foster 2004</a>). Currently available type I IFNs include IFN α‐2a (Roferon A® ‐ Roche), IFN α‐2b (Intron A® ‐ Schering), pegylated IFN α‐2a (Pegasys® ‐ Roche), pegylated IFN α‐2b (Pegatron® ‐ Schering), IFN β‐1a (Rebif® ‐ Pfizer, EMD Serono), IFN β‐1a (Avonex® ‐ Biogen Idec), IFN β‐1a (CinnoVex® ‐ CinnaGen, Fraunhofer Gessellschaff Institute), and IFN β‐1b (Betaseron® ‐ Bayer HealthCare). </p> <p><b>Importance of this review</b> <br/> In an effort to improve the management of UC, alternative therapeutic options need to be evaluated. Laboratory studies suggest that IFN treatment may attenuate chronic colitis. However, there is limited clinical information on the use of IFN therapy for UC, and there are concerns regarding its adverse effect profile. Furthermore, there is variation in the types of IFN (IFN‐α, IFN‐β), formulations (standard versus pegylated), doses and dosing schedules used in clinical practice. Therefore, a systematic review was planned to assess the role of type I IFN therapy for induction of remission in UC. This systematic review is an update of a previously published Cochrane systematic review (New Reference). </p> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006790-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006790-sec-0017"></div> <p>The primary objective of this review was to systematically evaluate the efficacy of type I IFN therapy (including IFN‐β‐1a, IFN‐β‐1b, IFN‐α‐2a, IFN‐α‐2b and associated pegylated formulations) for induction of remission in ulcerative colitis. The secondary objectives were to determine improvement in disease activity (including quality of life) and to evaluate adverse events associated with IFN therapy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006790-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006790-sec-0018"></div> <section id="CD006790-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006790-sec-0020"> <h4 class="title">Types of studies</h4> <p>Randomised, double‐blind trials reporting either the primary or secondary objective and published in any language, with the following study designs: parallel arm placebo‐controlled trials and trials comparing two active agents, were considered for this review. Studies published in abstract form were only included if enough data were provided to assess the validity of the study and reported outcomes. </p> </section> <section id="CD006790-sec-0021"> <h4 class="title">Types of participants</h4> <p>UC is usually diagnosed using a combination of clinical, radiologic, endoscopic and histologic criteria. Patients (both paediatric and adult) with active UC at the time of recruitment were included. It was anticipated that there would be heterogeneity in defining disease activity, therefore the definitions used by the authors of the primary studies were accepted. These included some of the following published disease activity indices: the Colitis Activity Index (CAI) (<a href="./references#CD006790-bbs2-0051" title="RachmilewitzD . Coated mesalazine (5‐aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ1989;298(6666):82‐6. ">Rachmilewitz 1989</a>), the Powell‐Tuck Index (<a href="./references#CD006790-bbs2-0050" title="Powell‐TuckJ , BownRL , Lennard‐JonesJE . A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scandinavian Journal of Gastroenterology1978;13(7):833‐7. ">Powell‐Tuck 1978</a>), the Simple Clinical Colitis Activity Index (SCCAI) (<a href="./references#CD006790-bbs2-0066" title="WalmsleyRS , AyresRC , PounderRE , AllanRN . A simple clinical colitis activity index. Gut1998;43(1):29‐32. ">Walmsley 1998</a>), Beattie's Colitis Symptom Score (<a href="./references#CD006790-bbs2-0018" title="BeattieRM , NichollsSW , DomizioP , WilliamsCB , Walker‐SmithJA . Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. Journal of Pediatric Gastroenterology and Nutrition1996;22(4):373‐9. ">Beattie 1996</a>), Lichtiger Symptom Score for Acute Ulcerative Colitis (<a href="./references#CD006790-bbs2-0046" title="LichtigerS , PresentDH . Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet1990;336(8706):16‐9. ">Lichtiger 1990</a>), the Mayo Index (<a href="./references#CD006790-bbs2-0053" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5‐aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625‐9. ">Schroeder 1987</a>), the Seo Index (<a href="./references#CD006790-bbs2-0055" title="SeoM , OkadaM , YaoT , UekiM , ArimaS , OkumuraM . An index of disease activity in patients with ulcerative colitis. American Journal of Gastroenterology1992;87(8):971‐6. ">Seo 1992</a>), the Truelove and Witt's Index (<a href="./references#CD006790-bbs2-0063" title="TrueloveSC , WittsLJ . Cortisone in ulcerative colitis; final report on a therapeutic trial. British Medical Journal1955;2(4947):1041‐8. ">Truelove 1955</a>), Ulcerative Colitis Scoring System (UCSS) (<a href="./references#CD006790-bbs2-0053" title="SchroederKW , TremaineWJ , IlstrupDM . Coated oral 5‐aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine1987;317(26):1625‐9. ">Schroeder 1987</a>) and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (<a href="./references#CD006790-bbs2-0062" title="TravisSP , SchnellD , KrzeskiP , AbreuMT , AltmanDG , ColombelJF , et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut2012;61(4):535‐42. ">Travis 2012</a>). </p> </section> <section id="CD006790-sec-0022"> <h4 class="title">Types of interventions</h4> <p>Trials assessing type I IFNs (IFN‐α or IFN‐β) compared to placebo, no treatment, different regimens of interferon or an active comparator were included. Co‐interventions were permitted if the co‐interventions were balanced across the study groups. There were no exclusions based on type, dose or duration of IFN treatment. </p> </section> <section id="CD006790-sec-0023"> <h4 class="title">Types of outcome measures</h4> <p><b>Primary outcome</b><br/> The primary outcome was induction of remission of UC. Remission was defined by the primary studies (see disease activity indices described under 'Types of participants') and was expressed as the percentage of patients randomised (intention‐to‐treat analysis). </p> <p><b>Secondary outcomes</b><br/> The secondary outcomes included:<br/> 1. Time to remission;<br/> 2. The mean change in the disease activity index score;<br/> 3. Clinical, histological or endoscopic improvement as defined by the authors;<br/> 4. Improvement in quality of life as defined by a validated quality of life tool; and<br/> 5. Adverse events associated with IFN therapy for the treatment of UC.<br/> Four different outcome measures were used to evaluate the safety of type I IFNs: </p> <p> <ul id="CD006790-list-0001"> <li> <p>The percentage of patients experiencing adverse events (which may have included but were not limited to flu‐like symptoms, skin rashes, psychological disturbances, perturbations in the haematological profile, and autoimmune complications such as thyroid disorders, diabetes mellitus and alopecia); </p> </li> <li> <p>The percentage of patient withdrawals due to adverse events;</p> </li> <li> <p>The percentage of patients undergoing colectomy; and</p> </li> <li> <p>Mortality expressed as a percentage.</p> </li> </ul> </p> </section> </section> <section id="CD006790-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <p><b>Search sources</b> <br/> A. Electronic searching (Please see <a href="./appendices#CD006790-sec-0037">Appendix 1</a> for a complete list of search strategies)<br/> 1. MEDLINE (1950 ‐ August 2014)<br/> 2. EMBASE (1980 ‐ August 2014)<br/> 3. Cochrane Central Register of Controlled Trials<br/> 4. Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders (IBD/FBD) Group Specialised Trial Register<br/> 5. Ongoing trials identified from ClinicalTrials.gov registry </p> <p>B. Hand searching using reference lists of trials and review articles identified by means of the computer‐assisted search. </p> <p>C. Proceedings from major gastroenterology meetings<br/> (American Gastroenterology Association, British Society of Gastroenterology, United European Gastroenterology Week) were manually searched from 2002 onwards. </p> <p>D. Pharmaceutical and personal contacts<br/> Relevant pharmaceutical companies that have or are involved in the development of the type I IFNs, and leaders in the field of inflammatory bowel disease were contacted to try and identify further unpublished studies. </p> </section> <section id="CD006790-sec-0025"> <h3 class="title" id="CD006790-sec-0025">Data collection and analysis</h3> <p><b>Study selection</b><br/> All the article abstracts identified by the above search strategies were reviewed for eligibility. The full text articles of potentially relevant studies were independently reviewed by YW and JKM for inclusion in the review. Review articles were also retrieved and reference lists were manually searched. Disagreements were resolved by consensus. Trials published in abstract form were only included if full details of the protocol and results could be obtained from the authors. </p> <p><b>Data collection</b><br/> The eligible articles were reviewed in duplicate (YW, JKM) and the results of the trials were abstracted onto specially designed data extraction forms which mandated the following information be recorded: </p> <p>1. General article information: Study title, first author, and year of publication.<br/> 2. Study design: Randomisation process, allocation concealment, and blinding.<br/> 3. Patient cohort: Countries in which study was performed, years patients were entered into the study, total number of patients screened, total number of patients randomised, inclusion/exclusion criteria, baseline characteristics (demographics, disease extent, disease severity).<br/> 4. Intervention: Type of IFN (α versus β), formulation of IFN (standard versus pegylated), route of administration, dose, and dosing schedule.<br/> 5. Control: No treatment, placebo, or details of co‐intervention.<br/> 6. Primary outcome: Proportion of patients achieving remission in the intervention and control groups. Where available, the median number of days to remission and the mean change in the disease activity index score will be recorded.<br/> 7. Secondary outcomes: Data on other clinical, histologic, endoscopic measures of disease activity; quality of life information; adverse events; withdrawal of participants from either the intervention or control group, where provided. </p> <p><b>Assessment of methodological quality of included studies</b> <br/> The methodological quality of the included studies was evaluated using the Cochrane risk of bias tool (<a href="./references#CD006790-bbs2-0039" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). This tool involves rating trials as high, low or unclear risk of bias for each of the following criteria: </p> <p> <ol id="CD006790-list-0002"> <li> <p>Random sequence generation;</p> </li> <li> <p>Allocation concealment;</p> </li> <li> <p>Blinding;</p> </li> <li> <p>Missing data and attrition;</p> </li> <li> <p>Outcome reporting; and</p> </li> <li> <p>Other sources of bias.</p> </li> </ol> </p> <p>The overall quality of the evidence supporting the primary and secondary outcomes was evaluated using the GRADE approach (<a href="./references#CD006790-bbs2-0034" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>; <a href="./references#CD006790-bbs2-0054" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). Outcome data are rated as being of high, moderate, low or very low quality evidence. Data from randomised controlled trials begin as high quality but can be downgraded based on the following criteria: </p> <p> <ol id="CD006790-list-0003"> <li> <p>Risk of bias in the included trials;</p> </li> <li> <p>Indirect evidence;</p> </li> <li> <p>Inconsistent findings (including unexplained heterogeneity);</p> </li> <li> <p>Imprecision (i.e. sparse data or wide confidence interval or both); and</p> </li> <li> <p>Reporting bias.</p> </li> </ol> </p> <p>The different quality ratings are interpreted as the likelihood that future research would affect the estimate of effect. An estimate of effect based on high quality evidence is unlikely to change with further research. If the overall evidence is of moderate quality further research may have an impact on our confidence in the estimate and may change the estimate. Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate when the evidence is rated as low quality. Very low quality research indicates significant uncertainty with the findings (<a href="./references#CD006790-bbs2-0034" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>; <a href="./references#CD006790-bbs2-0054" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). </p> <p><b>Statistical analysis</b> </p> <p>Measures of treatment effect<br/> Data were extracted from the original studies and converted into individual 2 x 2 tables (e.g. remission versus no remission x IFN versus control) for each study. The proportion of patients who entered remission was calculated and reported as a relative risk (RR) and 95% confidence interval (95% CI). Where appropriate, the number needed to treat (NNT) and risk difference (RD) was also calculated. This was determined using an intention‐to‐treat analysis, based on the total number of patients randomised to each of the two groups, and the number of patients in remission at the end of follow‐up in each group. For continuous variables, the results were presented as the mean difference (MD) and 95% CI or the standardised mean difference (SMD) when different scales were used to measure the same underlying construct. Where available, individual 2 x 2 tables for strata within studies were also abstracted. </p> <p>Meta‐analysis<br/> For pooled analyses we utilized a random‐effects or fixed‐effect model depending on clinical and statistical heterogeneity. </p> <p>Assessment of heterogeneity<br/> The studies were first independently assessed for clinical or methodological heterogeneity. Then, the I<sup>2</sup> measure was calculated to quantify inconsistency. The I<sup>2</sup> statistic describes the percentage of total variation across studies that was due to heterogeneity rather than chance. We interpreted I<sup>2</sup> as follows: 25% ‐ low heterogeneity, 50% ‐ moderate heterogeneity, 75% ‐ high heterogeneity (<a href="./references#CD006790-bbs2-0038" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). The Chi<sup>2</sup> test was also calculated. Being a relatively insensitive test for the presence of heterogeneity, a P‐value &lt; 0.10 was considered to be statistically significant. </p> <p>Subgroup analysis<br/> A priori subgroup analyses were planned for the different isoforms of type I IFN (IFN‐α versus IFN‐β), different formulations of IFN (standard versus pegylated), different doses, different durations of treatment, paediatric versus adult, and left‐sided colitis versus pancolitis. </p> <p>Sensitivity analysis<br/> We performed sensitivity analyses excluding poor quality studies and studies published in abstract form. There were insufficient eligible trials to construct a 'funnel plot' to assess publication bias (<a href="./references#CD006790-bbs2-0024" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>). </p> <p>Analyses were performed using the Review Manager software (RevMan 5.3.5, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). </p> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006790-sec-0026" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006790-sec-0026"></div> <section id="CD006790-sec-0027"> <h3 class="title">Description of studies</h3> <p>See Table of included studies (<a href="./references#CD006790-sec-0043" title="">Characteristics of included studies</a>), Table of excluded studies (<a href="./references#CD006790-sec-0044" title="">Characteristics of excluded studies</a>). </p> <p>The initial search yielded 211 non‐duplicated articles. Based on abstract review, all potential controlled trials and review articles were retrieved for full text review. A total of 29 full text manuscripts were obtained of which six randomised controlled trials (21 full‐text articles) were identified by the authors as being eligible for inclusion (See <a href="#CD006790-fig-0001">Figure 1</a>). Eight studies were excluded. Agreement among authors regarding the eligibility of the included studies was 100%. <a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a> was published as conference abstracts only. We contacted the lead author of the <a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a> trial but were unable to obtain any additional information about the study. </p> <div class="figure" id="CD006790-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006790-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>All six included studies (total of 517 patients) were conducted in adult patients aged 18 years and over. The studies can be differentiated by the comparison groups and formulation of interferon used. Five trials compared a type I IFN to placebo in patients with active UC of any anatomic extent (<a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a>; <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a>; <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a>; <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a>; <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a>). Of these, three studies compared IFN‐β‐1a injected subcutaneously three times a week to placebo (<a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a>; <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a>; <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a>); and one study compared pegylated IFN‐α injected subcutaneously once a week to placebo (<a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a>). The remaining trial compared IFN‐α‐2a to prednisolone enemas in patients with left sided UC (<a href="./references#CD006790-bbs2-0001" title="MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open, randomized study comparing systemic interferon‐a‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. Gut1999;45(Suppl V):A286. MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open‐labeled, randomized study comparing systemic interferon‐alpha‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. American Journal of Gastroenterology2001;96(6):1807‐15. ">Madsen 2001</a>). </p> <p><a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a> was a multi‐center phase II study in North America and Eastern Europe sponsored by Biogen Idec. This was a randomised, double blind, placebo‐controlled trial of 123 adult patients who had active ulcerative colitis with a total Mayo score of 6 to 13 points including a Mayo endoscopic subscore of at least 2, indicating moderate to severe endoscopic activity, despite prior or concomitant treatment. Patients were randomly assigned to IFNβ 30 μg intramuscularly twice a week for 12 weeks (n = 62), or placebo injections (n = 61). The primary endpoint was clinical response at week 8, defined as a decrease from baseline in the total Mayo score by 30% and at least a 3 point decrement, accompanied by a decrease in the subscore for rectal bleeding of at least 1 point or an absolute endoscopic subscore of 0 or 1. The secondary endpoints were the safety and tolerability of IFNβ and the percentage of subjects with a decrease in the SCCAI score of ≥ 3 points at week eight. </p> <p><a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> was conducted in Germany and the Czech Republic. This was a randomised, double‐blind, placebo‐controlled trial of 91 adult patients with steroid refractory, active UC defined by a CAI score of at least 8 points. Patients were randomly assigned to one of three groups. Patients in group one received three million international units (MIU) of IFN‐β‐1a by subcutaneous injection three times a week (n = 32). Patients in group two received one MIU of IFN‐β‐1a by subcutaneous injection three times a week (n = 30); and group three received placebo injections (n = 29). The total duration of treatment was eight weeks. The primary outcome was the response rate at the end of treatment. Response was defined as a reduction of six or more points on the CAI at week eight compared to baseline. Secondary endpoints included: the number of patients achieving a complete response (reduction of CAI to ≤4 points after 8 weeks of treatment); time until response; reduction of CAI after 4 and 8 weeks; reduction of the endoscopic index after 8 weeks; number of patients receiving colectomy; and reduction of steroid dose. </p> <p><a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a> compared the effects of IFN‐β‐1a to placebo. The study was conducted in three countries; Belgium, Canada and Germany. This was a randomised, double blind, intra‐individual, dose escalating trial of 17 adult patients with moderately active UC. This was defined by a UCSS score of 6 to 10, with a proctosigmoidoscopy score of 2. Patients were randomly assigned to IFN‐β‐1a by subcutaneous injection three times a week (n = 10) or placebo injections (n = 7). Patients in the IFN‐β‐1a group were started at 22 μg three times a week by subcutaneous injection. Dose escalation was dependent on 'improvement'. Improvement was defined as a decrease of one point in the combined score of UCSS symptoms and physician's global assessment (PGA). If no improvement was observed after six injections, the dose was increased to 44 μg three times a week. If no improvement was observed after six injections at the 44 μg dose, this was increased further to 88 μg three times a week. If improvement was observed after six injections at any dose, the patient entered a maintenance treatment phase of 6 to 12 injections at that dose. If no improvement was observed after six injections at 88 μg, or if remission occurred at any point, treatment was stopped. The maximum duration of treatment was eight weeks, and the minimum duration was four weeks. The primary end point was efficacy, which was defined by treatment response and remission. Treatment response was defined by a decrease of at least three points from baseline in the UCSS symptoms score and PGA (without the proctosigmoidoscopic score) during treatment. Remission was defined as complete resolution of clinical symptoms (all clinical UCSS subscores equal to zero), with a proctosigmoidoscopy score of zero or one at any time during treatment. Secondary end points included overall treatment and end point responses (defined as a decrease in UCSS symptoms score, PGA, and proctosigmoidoscopic scores of at least one point during or at the end of treatment), and clinical end point responses (a decrease of at least one point from baseline in UCSS symptoms scores and PGA, without the proctosigmoidoscopic score). Safety data were also collected. </p> <p><a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> was an European phase II clinical trial sponsored by EMD Serono. The study was randomised, multi‐centred, double‐blinded, and placebo‐controlled. The trial involved 194 patients with moderately active ulcerative colitis, defined by a UCSS score between 6 and 10 with a UCSS PGA of less than three and a proctosigmoidoscopy score of two or three. Patients were randomised using stochastic minimization to one of three trial arms: IFN‐β‐1a 44 μg (n = 65), IFN‐β‐1a 66 μg (n = 65), or matching (same excipients but no IFN‐β‐1a) placebo (n = 64). All study drugs were given by subcutaneous injection three times a week for eight weeks and there was a four week follow‐up period.The primary objective was to identify the best dose of IFN‐β‐1a for the induction of endoscopically confirmed remission and examine the safety profile of this dose. Safety, tolerability, quality of life and biological markers were also assessed as secondary outcomes. </p> <p><a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> compared the effects of pegylated IFN‐α (PegIFN) to placebo. The study was conducted in five university hospitals in four countries including Austria, Belgium, Germany and France. This was a multicentre double‐blind randomised controlled trial of 60 adults with UC. Patients were randomly assigned to PegIFN 0.5 μg/kg (n = 19); PegIFN 1.0 μg/kg (n = 21); or placebo (n = 20). All therapies were administered by subcutaneous injection once a week, for a period of 12 weeks. Patients were eligible if they had evidence of clinical activity despite oral or topical 5‐aminosalicylate maintenance therapy, stable doses of steroids or azathioprine. Active disease was defined by a CAI score of greater than six, and endoscopic activity was defined by a Rachmilewitz endoscopy score of greater than four. Clinical evaluation was performed before the start of treatment (day ‐8), then on days 0, +8, +15, +29, +43, +57, and at the end of treatment (day +85). Patients underwent sigmoidoscopy and/or colonoscopy on days ‐1, +29, and +85. The primary outcome was safety. All adverse events were recorded and classified as serious or non‐serious, and likely or unlikely to be related to treatment. Other outcomes included disease remission (defined as a CAI score of less than or equal to four), endoscopic remission (defined as a score of less than four), and histological activity (graded on a scale from zero to three). These markers of remission were measured at week 12. Changes in serological inflammatory indices including haemoglobin, white cell count, platelet count, C reactive protein, α‐1 acid glycoprotein, creatinine, liver function tests, and albumin were also recorded. </p> <p><a href="./references#CD006790-bbs2-0001" title="MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open, randomized study comparing systemic interferon‐a‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. Gut1999;45(Suppl V):A286. MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open‐labeled, randomized study comparing systemic interferon‐alpha‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. American Journal of Gastroenterology2001;96(6):1807‐15. ">Madsen 2001</a> compared the effects of IFN‐α‐2a to prednisolone enemas. The study was conducted in Denmark. This was an open‐label, randomised controlled trial of 32 adult patients. The patient cohort was restricted to those with active left‐sided UC. Patients were randomly assigned to IFN‐α‐2a therapy by subcutaneous injection three times a week (n = 16) for 12 weeks; or prednisolone enemas 100 mL (25 mg) daily for 30 consecutive days (n = 16). The dose of IFN used was 9 MIU for the first week, 6 MIU for the second week, and 3 MIU from weeks 3 to 12 inclusive. All patients were treated with sulfasalazine or mesalazine compounds with a median daily dose of 2.4 g (range 1.2 to 3.6 g), and were not allowed dose adjustments for at least four weeks before entry. The patients receiving enemas were evaluated after one week, two weeks and on completion of the trial; while the IFN‐α‐2a group had appointments after one week, two weeks, four weeks, eight weeks, and after completion of the trial. Clinical and endoscopic disease activity was graded at each visit by semi‐quantitative scales. Clinical activity assessment was based on the patient filling out a five point symptom scale daily; while a physician evaluated abdominal tenderness, enquired about limitations in the patient's daily activities, adverse events and extraintestinal manifestations at each clinic visit. Endoscopic evaluation involved proctoscopy or colonoscopy at each clinic visit, and histological assessment of disease activity (rectal biopsies) were obtained at entry and after treatment. The combined clinical and endoscopic Powell‐Tuck Index was also calculated. Secondary outcomes included an assessment of quality of life, and tolerability of treatment. Remission was not defined by the authors, rather, the change in the activity indices were measured. </p> </section> <section id="CD006790-sec-0028"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk bias assessment results are summarized in <a href="#CD006790-fig-0002">Figure 2</a>. A table detailing withdrawals or drop outs is provided (<a href="#CD006790-tbl-0002">Table 1</a>). While none of the studies were excluded on this basis, the studies have to be interpreted with caution given the substantial proportion of withdrawals or drop outs. </p> <div class="figure" id="CD006790-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006790-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="table" id="CD006790-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overall withdrawals (%); Placebo versus Type I IFNs</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IFN Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High dose IFN</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low dose IFN</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.6</p> </td> </tr> </tbody> </table> </div> <p><a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a> did not report on methods used for randomisation or allocation concealment. These items were rated as unclear. Patient drop‐out data were not included in the abstract publications, but analyses were conducted on an intention‐to‐treat basis. Based on ClinicalTrial.gov (NCT00616434), 10% (6/62) of patients in the IFNβ‐1a 30 μg treatment group and 13% (8/61) of patients in the placebo group did not complete the study. <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> was reported as randomised but the methods used to generate the random sequence were not described. There was an adequate description of the blinding process as well as allocation concealment. The drop‐out rate was 12% (4/32) in the 3 MIU IFN‐β‐1a group, 17% (5/30) in the 1 MIU IFN‐β‐1a group, and 24% (7/29) in the placebo group. <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a> was a well designed but small study. However, there was a substantial drop out rate particularly in the intervention (IFN‐β‐1a) group where 60% (6/10) of patients withdrew. The withdrawal rate in the control group was 29% (2/7). There was a detailed description of the use of a centralised, computer generated list for randomisation. Study subjects were stratified by centre with a block size of three (a ratio of 2 to 1: IFN‐β‐1a to placebo). Allocation concealment was not described. The study design was described as double blind, but further details on how this was achieved were not reported. An intention‐to‐treat analysis was utilised. <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> provided adequate descriptions regarding randomisation, allocation concealment, blinding and outcome data. Twenty per cent (13/65) of patients in 66 μg IFN‐β‐1a treatment group, 22% (14/65) of patients in 44 μg IFN‐β‐1a treatment group, and 17% (11/64) of patients in placebo group withdrew from the study. All efficacy endpoints were analysed using intention‐to‐treat (ITT) populations. <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> was described as randomised, but there was no information provided on the generation of the randomisation sequence, nor on blinding or allocation concealment. Thirty‐two per cent (6/19) of patients in the PegIFN‐α 0.5 μg/kg group withdrew from the study, compared to 48% (10/21) of patients in the PegIFN‐α 1.0 μg/kg group, and 55% (11/20) of patients in the control group. The results were interpreted with caution given the high drop out rate. <a href="./references#CD006790-bbs2-0001" title="MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open, randomized study comparing systemic interferon‐a‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. Gut1999;45(Suppl V):A286. MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open‐labeled, randomized study comparing systemic interferon‐alpha‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. American Journal of Gastroenterology2001;96(6):1807‐15. ">Madsen 2001</a> was an open‐label study. There was an adequate description of the randomisation process (using a computer generated random number generator), as well as allocation concealment. All 16 patients in the prednisolone enema (control) group completed the trial compared to a withdrawal rate of 19% (3/16) in the IFN‐α‐2a group. </p> </section> <section id="CD006790-sec-0029"> <h3 class="title" id="CD006790-sec-0029">Effects of interventions</h3> <p>See: <a href="./full#CD006790-tbl-0001"><b>Summary of findings for the main comparison</b> Type I Interferons compared to placebo for induction of remission in ulcerative colitis</a> </p> <p><b>Primary Outcome</b><br/> The primary outcome was induction of remission of UC. Of the six studies satisfying the inclusion criteria, four studies reported on the proportion of patients achieving remission at the end of treatment (<a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a>; <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a>; <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a>; <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a>). There were three studies that compared IFN‐β‐1a versus placebo albeit using different formulations and doses (<a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a>; <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a>; <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a>), and one study comparing PegIFN‐α versus placebo (<a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a>). </p> <p>After 8 weeks of treatment in the <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> study, 56% (18/32) of patients in the IFN‐β‐1a 3 MIU group achieved remission, compared to 30% (9/30) of the 1 MIU group and 38% (11/29) in the placebo group. The difference between the 3 MIU and the 1 MIU group was statistically significant with a P = 0.04, but not significant when compared with placebo. The authors concluded that IFN‐β‐1a was not more effective than placebo in steroid‐refractory UC. The non‐pooled dose‐dependent data are presented in <a href="#CD006790-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD006790-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Type I Interferons versus placebo, outcome: 1.1 Remission (non pooled data)." data-id="CD006790-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Type I Interferons versus placebo, outcome: 1.1 Remission (non pooled data). </p> </div> </div> </div> <p>In the IFN‐β‐1a dose escalating study by <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a>, 30% (3/10) of the intervention group achieved remission compared to 0% in the placebo group. One patient received 44 μg IFN‐β‐1a injections whilst two were treated with 88 μg IFN‐β‐1a injections. The authors concluded that patients treated with escalating doses of IFN‐β‐1a tended to show a higher remission rate than those in the placebo group, however, the difference between the groups was not statistically significant. </p> <p>In the <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> study clinical remission was achieved by 35.4% (23/65) of patients treated in the 44μg IFN‐β‐1a group, 27.7% (18/65) of those in the 66μg IFN‐β‐1a group, and 28.1% (18/64) of patients in the placebo group. The differences between the groups were not statistically significant. Please note, only percentages were reported in the original publication, absolute numbers in brackets were calculated using the intention to treat population. </p> <p><a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> used a CAI of ≤ 4 to define remission. At week 12, 7/21 (33.3%) of the 1.0 μg/kg PegIFN‐α group, 9/19 (47.4%) of the 0.5 μg/kg and 7/20 (35.0%) in the placebo group achieved remission. The authors concluded that there was no significant advantage of PegIFN over placebo. </p> <p>Data from four studies were pooled in a meta‐analysis. While three of the studies used IFN‐β‐1a (<a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a>; <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a>; <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a>), and one study used PegIFN‐α (<a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a>), the authors felt there was sufficient clinical homogeneity across both IFN preparations in immunological action, such that the data could be meta‐analysed. There was no statistically significant difference in remission rates between IFNs and placebo. Thirty‐six per cent (87/242) of IFNs patients achieved remission compared to 30% (36/120) of placebo patients (RR 1.16, 95% CI 0.84 to 1.58; P = 0.37). A GRADE analysis indicated that the quality of evidence supporting the outcome clinical remission was moderate due to sparse data (See <a href="./full#CD006790-tbl-0001">summary of findings Table for the main comparison</a>). However, these results should be interpreted with caution given variability in dosing, treatment duration, and the timing of outcome assessment. <a href="#CD006790-tbl-0003">Table 2</a> documents the comparative doses of IFN‐b‐1a used in the <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a>, <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a> and <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> trials. A 44 μg dose is approximately equivalent to 12 MIU (<a href="./references#CD006790-bbs2-0016" title="AntonettiF , FinocchiaroO , MasciaM , TerlizzeseMG , JaberA . A comparison of the biologic activity of two recombinant IFN‐beta preparations used in the treatment of relapsing‐remitting multiple sclerosis. Journal of Interferon &amp; Cytokine Research2002;22(12):1181‐4. ">Antonetti 2002</a>). Although the <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> trial suggested that remission may be dose dependent, the dosing was still lower than that used in the <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a> trial preventing comparisons of high versus low dose IFN across studies. The comparison was further confounded by differing durations of treatment; 8 weeks (56 days) in the <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> and <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> trials compared to approximately 5 weeks (35.5 days) in the <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a> study. </p> <div class="table" id="CD006790-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Comparative IFN‐b‐1a Doses used in the Nikolaus, Musch and Pena‐Rossi Trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose of IFN‐b‐1a</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Remission (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>%</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nikolaus 2003: Median treatment duration 35.5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88mcg t.i.w</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44mcg t.i.w.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22mcg t.i.w.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL (Nikolaus)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Musch 2005: Treatment duration: 56 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3MIU t.i.w. = 11mcg t.i.w.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1MIU t.i.w. = 3.7mcg t.i.w.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL (Musch)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>[12MIU = 44mcg] Reference: Antonetti 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pena‐Rossi 2008: Treatment duration: 56 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66mcg t.i.w.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44mcg t.i.w.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL (Pena‐Rossi)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.5</p> </td> </tr> </tbody> </table> </div> <p>A priori subgroup and sensitivity analyses were planned for the different IFN isoforms and according to study quality. The analysis was repeated excluding the <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> study as patients were treated with the α−isoform preparation and this was the only study that was judged to be low quality. Analysis of the three IFN‐β‐1a, moderate quality studies (<a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a>; <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a>; <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a>), did not change the results (RR 1.19, 95% CI 0.84 to 1.69). </p> <p><b>Secondary outcomes<br/> <br/> <i>1. Time to remission</i> </b> (in days)<br/> Two studies using IFN‐β‐1a reported on the mean number of days to remission (<a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a>; <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a>). In the <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> study, the time to complete response (remission) was 32.1 ± 17.9 days in the 3 MIU group; 34.3 ± 20.0 days in the 1 MIU group and 36.2 ± 16.4 days in the placebo group. The differences in mean time to remission were not statistically significant between the groups. <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a> reported the mean time to remission was 52 ± 7 days in the IFNs group. There were no patients in the placebo group who achieved remission within the study time frame. <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> did not provide sufficient data for comparison. <a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a>, <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> and <a href="./references#CD006790-bbs2-0001" title="MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open, randomized study comparing systemic interferon‐a‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. Gut1999;45(Suppl V):A286. MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open‐labeled, randomized study comparing systemic interferon‐alpha‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. American Journal of Gastroenterology2001;96(6):1807‐15. ">Madsen 2001</a> did not report on this outcome. </p> <p><i><b>2. Change in the disease activity index score</b> </i> <br/> The change in disease activity index scores could not be pooled given the heterogeneity of indices and the differing time of outcome measurement used. </p> <p><a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> reported the median change in CAI at four and eight weeks. All patients started with a CAI score of 10; at 4 weeks, there was a reduction of 5 points in the CAI in the 3 MIU group, 3 points in the 1 MIU group, and 4 points in the placebo group. The median change in CAI at eight weeks was six points in the 3 MIU group, three points in the 1 MIU group, and four points in the placebo group. There was no statistically significant difference between the three groups at either time point. <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> measured the CAI at baseline and weeks 1, 2, 4, 6, 8 and 12. Results were reported as the mean score and standard deviation. Using the <a href="./references#CD006790-bbs2-0027" title="FollmannD , ElliottP , SuhI , CutlerJ . Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology1992;45(7):769‐73. ">Follmann 1992</a> method, the mean change in the CAI and standard deviation were calculated. The mean reduction in CAI from baseline to week 12 was 4.0 ± 2.5 in the 1.0 μg/kg group, 4.9 ± 2.3 in the 0.5 μg/kg group and 6.3 ± 2.8 in the placebo group. </p> <p>Both <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> and <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> reported on end of treatment change in endoscopic index scores. <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> provided both the mean and median reduction of the endoscopic index score at eight weeks, while <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> reported on endoscopic index values at baseline, week 4 (day 29), and at week 12 (day 85). Using the <a href="./references#CD006790-bbs2-0027" title="FollmannD , ElliottP , SuhI , CutlerJ . Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology1992;45(7):769‐73. ">Follmann 1992</a> method, the mean change in endoscopic index score and standard deviation were calculated for the <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> study. The mean reduction in scores in the <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> study was 4.4 ± 3.4 points in the 3 MIU group, 3.3 ± 4.1 in the 1 MIU group and 3.6 ± 3.4 points in the placebo group. The mean reduction in scores in the <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> study was 3.6 ± 2.4 in the 1.0 μg/kg PegIFN‐α group, 3.2 ± 3.6 in the 0.5 μg/kg group, and 4.0 ± 3.2 in the placebo group. The change in endoscopic index scores was not statistically significant in either study. </p> <p>There were no statistically significant differences in any of the UCSS subscores between the IFN‐β‐1a and placebo groups four weeks after the end of treatment in the <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a> study. The change in UCSS symptom scores are as reported as follows: UCSS subscore type, change in score for IFN‐β‐1a group, change in score for the placebo group. Stool frequency, ‐1.0 ± 1.2, ‐0.14 ± 0.89; rectal bleeding, ‐0.4 ± 1.1, ‐0.42 ± 0.79; physician global assessment ‐0.56 ± 1.2, ‐0.38 ± 0.92; proctosigmoidoscopy score ‐0.8 ± 1.1, 0.14 ± 0.69. </p> <p><a href="./references#CD006790-bbs2-0001" title="MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open, randomized study comparing systemic interferon‐a‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. Gut1999;45(Suppl V):A286. MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open‐labeled, randomized study comparing systemic interferon‐alpha‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. American Journal of Gastroenterology2001;96(6):1807‐15. ">Madsen 2001</a> reported a statistically significant improvement from baseline in the Powell‐Tuck Index in the IFN‐α‐2a group (P = 0.0002), and in the prednisolone enema group (P = 0.0009). The median score in the IFN‐α‐2a group at baseline was 9.0 (95% CI 7.2 to 10.4), and post treatment 1.5 (95% CI 1.2 to 4.5). For the prednisolone enema group, the baseline score was 8 (95% CI 6.5 to 9.0) and post treatment 3 (95% CI 1.9 to 5.6). There was no statistically significant difference in Powell‐Tuck scores between the intervention groups. </p> <p><a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a> and <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> did not provide sufficient data for comparison. </p> <p><i><b>3. Clinical, histological or endoscopic improvement</b> </i> <br/> <a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a> reported the percentage of participants with a clinical response, defined as a decrease from baseline in the total Mayo score of at least 3 points and at least 30%, accompanied by a decrease in the subscore for rectal bleeding of at least 1 point or an absolute subscore of 1 or less. 53% (33/62) in IFN‐β‐1a group and 44% (27/61) in placebo group achieved a clinical response. There was no statistically significant difference between the groups. </p> <p><a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> reported the proportion of patients achieving a clinical response at the end of treatment, defined by a reduction of 6 or more CAI points after the 8 week treatment period. In the 3 MIU IFN‐β‐1a group, 18/32 (56%) achieved a clinical response, this was achieved by 11/30 (36%) in the 1 MIU group, and 10/29 (34%) in the placebo group. There was no statistically significant difference between the groups. </p> <p><a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a> reported the percentage of patients who achieved a clinical response (distinct from remission), which was defined as a decrease of at least 3 points in the UCSS. This was achieved by 5/10 (50%) in the IFN‐β‐1a group compared to 1/7 (15%) in the placebo group (P = 0.14). </p> <p><a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> reported the percentage of patients who achieved a clinical response (≥3‐point decrease in UCSS and PGA scores), which was achieved in 64.6% (42/65) of IFN‐β‐1a 44 μg group, 61.5% (40/65) of IFN‐β‐1a 66 μg group, and 60.9% (39/64) of placebo group. </p> <p>Data from four studies were pooled in a meta‐analysis. There was no statistically significant difference in clinical improvement remission rates between IFNs and placebo. Fifty‐six per cent (149/264) of IFN treated patients improved clinically compared to 48% (77/161) of placebo patients (RR 1.16, 95% CI 0.96 to 1.40; P = 0.13). A GRADE analysis indicated that the quality of evidence supporting this outcome was moderate due to sparse data (See <a href="./full#CD006790-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p><a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> reported the proportion of patients achieving endoscopic remission (defined by an endoscopic activity score of &lt; 4 at 12 weeks). In the 1.0 μg/kg PegIFN‐α group, 20% achieved this secondary endpoint, compared to 18% in the 0.5 μg/kg group and 26% in the placebo group. The authors reported that there was no difference in endoscopic activity between the three treatment groups at any time point. Rectal histological activity was assessed in a subgroup of patients, however at the end of treatment at week 12 (day 85), the data were too limited to allow comparison. </p> <p><a href="./references#CD006790-bbs2-0001" title="MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open, randomized study comparing systemic interferon‐a‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. Gut1999;45(Suppl V):A286. MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open‐labeled, randomized study comparing systemic interferon‐alpha‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. American Journal of Gastroenterology2001;96(6):1807‐15. ">Madsen 2001</a> utilised clinical and endoscopic activity scores to document disease but these scoring systems were semi‐quantitative and not validated. </p> <p><i><b>4. Improvement in quality of life</b> </i> <br/> <a href="./references#CD006790-bbs2-0001" title="MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open, randomized study comparing systemic interferon‐a‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. Gut1999;45(Suppl V):A286. MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open‐labeled, randomized study comparing systemic interferon‐alpha‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. American Journal of Gastroenterology2001;96(6):1807‐15. ">Madsen 2001</a> used the Inflammatory Bowel Disease Questionnaire (IBDQ) to assess quality of life (<a href="./references#CD006790-bbs2-0033" title="GuyattG , MitchellA , IrvineEJ , SingerJ , WilliamsN , GoodacreR , et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology1989;96(3):804‐10. ">Guyatt 1989</a>). The following results represent an ITT analysis in patients with disease extension exceeding the rectum. The IBDQ has not been validated in patients with proctitis alone. Of the 12 patients randomised to IFN‐α‐2a, the baseline median IBDQ (total) score was 166 (95% CI 145.3 to 181.4), and post treatment was 193.5 (95% CI 181.0 to 204.6). The difference in scores from baseline for the IFNs group was statistically significant (P = 0.002). In the prednisolone enema group, there was no statistically significant difference before and after treatment (P = 0.055). The baseline median IBDQ score in the prednisolone enema group was 181 (95% CI 165.3 to 197.2) and the post treatment score was 207 (95% CI 178.5 to 215.3). There was no statistically significant difference in IBDQ scores between the treatment groups. </p> <p><a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> reported IBDQ scores as a secondary endpoint. The IBDQ improved meaningfully (≥15‐point improvement) in 41% (26/64) of patients in the placebo group compared to 48% (31/65) of the IFN‐β‐1a 44 μg group, and 44.6% (29/65) of the IFN‐β‐1a 66 μg group. </p> <p><i><b>5. Adverse events</b> </i> <br/> a. Adverse eventsThe most common adverse events experienced by patients were consistent with the known side effect profile of IFNs and included headaches, arthralgias, myalgias, fatigue, back pain, nausea, application site reactions, rigors, and fevers. The adverse event profile of the different isoforms of IFN appeared similar. It was not possible to meta‐analyse these adverse events due to variability in reporting. For example, a large number of patients experienced adverse events in the <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a> study, 100% of patients experienced at least one adverse event and 97% of these events were graded as mild or moderate in severity. In the <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> trial, 68.1% of patients experienced adverse events. However adverse events were not reported according to treatment allocation. <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> tabulated all adverse events but did not report them per patient. There were 13 adverse effects in the placebo group, 47 in the PegIFN 0.5 mg/kg group, and 45 in the PegIFN 1.0 mg/kg group. <a href="./references#CD006790-bbs2-0001" title="MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open, randomized study comparing systemic interferon‐a‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. Gut1999;45(Suppl V):A286. MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open‐labeled, randomized study comparing systemic interferon‐alpha‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. American Journal of Gastroenterology2001;96(6):1807‐15. ">Madsen 2001</a> reported that adverse events only occurred in the IFNs group. A table of adverse events was provided on a time line, using a semi‐quantitative scale. However, this does not allow one to determine the total number of patients suffering an adverse event and the tolerability of treatment was assessed by the patient rather than the physician. The largest number of adverse events was reported during week one, where 35 events were reported by an undisclosed number of patients in the IFN‐a‐2a group. The authors commented that the adverse events were generally mild to moderate with the most common being flu‐like symptoms. <a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a> reported that 84% (52/62) of the IFN‐β‐1a group experienced at least one adverse event compared to 57% (35/61) of placebo patients. A more detailed breakdown of the adverse events is reported on ClinicalTrials.gov. <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> listed common (&gt;10% of patients) and less common (&lt;10% of patients) adverse events and tabulated data for some mild to moderate adverse effects (e.g. headache, fever, influenza‐like symptoms, and application‐site disorders) and serious adverse effects. </p> <p>Serious adverse events were more clearly documented. <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> reported 7 serious adverse events in 5 patients; 1/32 (3.1%) in the 3 MIU IFN‐β‐1a group experienced chest pain while 4/29 (13.8%) in the placebo group experienced a variety of adverse events including worsening UC symptoms, infection, and a respiratory disorder. There were no serious adverse events documented in the 1 MIU IFN group. <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> reported that 3/21 (14.3%) in the 1.0 μg/kg group and 3/19 (15.8%) in the 0.5 μg/kg group experienced serious adverse events. The three adverse events in the higher dose (1.0 μg/kg IFN) group included a disease flare, thrombosis of the brachiocephalic vein, and a grand mal seizure. All serious adverse events in the 0.5 μg/kg group were related to lack of efficacy, resulting in hospitalisation and intensification of treatment in the three patients. There were no serious adverse events in the placebo group. <a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a> found 4 serious adverse events, one (1/62, 1.61%) with worsening of ulcerative colitis in the IFN‐β‐1a group, and three in the placebo group (3/61, 4.92%), of which, two patients experienced worsening of UC and one patients had a tibial fracture. <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> reported five serious adverse events (one event in the placebo group and two in each of the IFN‐β‐1a groups), A pooled analysis of four studies showed no statistically significant difference in the proportion of patients who experienced a serious adverse event. Four per cent (12/294) of IFN patients had a serious adverse event compared to 5% (8/174) placebo patients (RR 0.74, 95% CI 0.13 to 4.14). A GRADE analysis indicated that the quality of evidence supporting this outcome was low due to very sparse data (See <a href="./full#CD006790-tbl-0001">summary of findings Table for the main comparison</a>). A sensitivity analysis excluding an abstract publication did not change the results (RR 1.03, 95% 0.10 to 10.87). </p> <p>b. Withdrawals (including those due to adverse events)</p> <p>Eighteen per cent (16/91) of patients withdrew from the <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> study. Withdrawal was most common in the placebo group at 24% followed by 17% in the low dose IFNs group and 12% in the high dose IFNs group. Reasons for discontinuation included two withdrawals due to worsening health and one withdrawal due to intolerable adverse events. However, the authors did not report which study medication these patients received. <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a> reported a 29% (2/7) withdrawal rate amongst placebo treated patients, and a substantial 60% (6/10) non‐completion rate amongst IFNs treated individuals. Both of the placebo patients who withdrew and four of six IFNs patients withdrew due to progressive disease. One IFNs patient withdrew due to an adverse event (influenza like symptoms). There were no withdrawals due to adverse events in the placebo group. A high withdrawal rate was documented in the <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> study. More than half (11/20 = 55.0%) of the placebo patients dropped out, compared to 48% (10/21) of the high dose IFNs group, and 32% (6/19) in the low dose IFNs group. Of these, one individual (1/20 = 5%) in the placebo group and 2 patients (2/21 = 10%) in the high dose IFNs group withdrew due to adverse events (fever in the placebo treated patients, and unspecified 'serious' adverse events in the IFNs patients), while the remaining individuals withdrew due to disease progression. In the <a href="./references#CD006790-bbs2-0001" title="MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open, randomized study comparing systemic interferon‐a‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. Gut1999;45(Suppl V):A286. MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open‐labeled, randomized study comparing systemic interferon‐alpha‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. American Journal of Gastroenterology2001;96(6):1807‐15. ">Madsen 2001</a> study, there were 3/16 (19%) withdrawals in the IFNs group, two of these patients were noted to have abnormal liver biochemistry and one experienced progressive disease. No patients withdrew from the prednisolone enema group. <a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a> reported that 8% (5/62) of IFNs patients withdrew due to adverse events, compared to 3% (2/61) of placebo patients. Details of the adverse events were not reported. In <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> study, ten patients withdrew from the study because of adverse events ‐ four in the IFN‐β‐1a 44 μg group, six in the IFN‐β‐1a 66 μg group, and none in the placebo group. In the IFN‐β‐1a 44 μg group, two patients withdrew because of constitutional symptoms and one withdrew due to severe thrombocytopenia, anemia and macrohematuria concurrent with an exacerbation of ulcerative colitis. In the IFN‐β‐1a 66 μg group, three patients withdrew because of constitutional symptoms and one patient discontinued because of worsening of UC. </p> <p>The data were meta‐analysed in two ways: firstly, comparing the overall withdrawal rate amongst type I IFNs against placebo; then comparing the withdrawal rate due to adverse events for the same groups. A fixed‐effect model was used for the overall withdrawal rate as there was minimal heterogeneity (P = 0.40, I<sup>2</sup>=2.0%). All five placebo‐controlled studies were used for the analysis, with a total of 485 patients (<a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a>; <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a>; <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a>; <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a>; <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a>). There was no statistically significant difference in withdrawal rates. Twenty‐one per cent (64/304) of patients in the IFNs group withdrew before the end of the study compared to 22% (39/181) of placebo patients (RR 0.91, 95% CI 0.65 to 1.29; P = 0.90). A sensitivity analysis excluding an abstract publication did not change the results (RR 0.95, 95% CI 0.66 to 1.36). A fixed‐effect model was used for withdrawal due to adverse events as there was no evidence of statistical heterogeneity (P = 0.62, I<sup>2</sup> = 0%). Four trials with a total of 394 patients were included in this comparison (<a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a>; <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a>; <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a>; <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a>). There was a statistically significant difference in withdrawals due to adverse events. Seven per cent (18/242) of patients in the IFNs group withdrew due to adverse events compared to 2% (3/152) of placebo patients (RR 3.16, 95% CI 1.06 to 9.40; P = 0.03). A GRADE analysis indicated that the quality of evidence supporting this outcome was low due to very sparse data (See <a href="./full#CD006790-tbl-0001">summary of findings Table for the main comparison</a>). <br/> c. Colectomy<br/> In the <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> study, two patients underwent colectomy, 1/32 (3.1%) in the 1 MIU IFN‐β‐1a group at 8 weeks, and 1/29 (3.4%) in the placebo group 3 weeks into the trial. <a href="./references#CD006790-bbs2-0001" title="MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open, randomized study comparing systemic interferon‐a‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. Gut1999;45(Suppl V):A286. MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open‐labeled, randomized study comparing systemic interferon‐alpha‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. American Journal of Gastroenterology2001;96(6):1807‐15. ">Madsen 2001</a> reported 1/16 (6.2%) patients in the IFN‐α‐2a group required a colectomy. There were no colectomies in the prednisolone enema control group (<a href="./references#CD006790-bbs2-0001" title="MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open, randomized study comparing systemic interferon‐a‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. Gut1999;45(Suppl V):A286. MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open‐labeled, randomized study comparing systemic interferon‐alpha‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. American Journal of Gastroenterology2001;96(6):1807‐15. ">Madsen 2001</a>). <a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a>, <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a>, <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> and <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> did not report this outcome. </p> <p>d. Mortality<br/> There were no deaths reported in any of the six included studies. </p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006790-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006790-sec-0030"></div> <p>Moderate quality evidence suggests that type I IFNs are not effective for the treatment of patients with active UC (<a href="./references#CD006790-bbs2-0001" title="MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open, randomized study comparing systemic interferon‐a‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. Gut1999;45(Suppl V):A286. MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open‐labeled, randomized study comparing systemic interferon‐alpha‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. American Journal of Gastroenterology2001;96(6):1807‐15. ">Madsen 2001</a>; <a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a>; <a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a>; <a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a>; <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a>; <a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a>). Meta‐analysis of placebo‐controlled studies showed no difference in clinical remission or response rates. There was no difference in the time to remission nor a difference in endoscopic activity index scores following treatment with IFN compared to placebo. The only study to show a statistically significant improvement in a clinical activity index and quality of life compared treatment with IFN‐α‐2a to prednisolone enemas in patients with left‐sided colitis (<a href="./references#CD006790-bbs2-0001" title="MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open, randomized study comparing systemic interferon‐a‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. Gut1999;45(Suppl V):A286. MadsenSM , SchlichtingP , DavidsenB , NielsenOH , FederspielB , RiisP , et al. An open‐labeled, randomized study comparing systemic interferon‐alpha‐2A and prednisolone enemas in the treatment of left‐sided ulcerative colitis. American Journal of Gastroenterology2001;96(6):1807‐15. ">Madsen 2001</a>). The response to therapy may reflect the limited extent of the disease in these patients. The results of this study should be interpreted with caution due to risk of bias (i.e. open‐label design) and the small number of patients enrolled. </p> <p>The most common adverse events related to IFN therapy included headaches, arthralgias, myalgias, fatigue, back pain, nausea, application site reactions, rigors, and fever. There did not appear to be a difference in the adverse event profile of the different isoforms of IFN. There were no differences in the proportion of patients experiencing 'serious' adverse events which were defined as those that required specific treatment, including but not limited to escalation of therapy for UC, hospitalisation, or any symptoms which led to withdrawal from the trial. Based on the pooled data from four trials, there was an increased rate of withdrawals due to adverse events in IFN treated patients. </p> <p>The above data could not fully address concerns raised by a handful of case reports that suggest that IFN therapy may exacerbate UC (<a href="./references#CD006790-bbs2-0065" title="TursiA . Rapid onset of ulcerative colitis after treatment with PEG‐interferon plus ribavirin for chronic hepatitis C. Inflammatory Bowel Diseases2007;13(9):1189‐90. ">Tursi 2007</a>; <a href="./references#CD006790-bbs2-0067" title="WatanabeT , InoueM , HaradaK , HommaN , UchidaM , OgataN , et al. A case of exacerbation of ulcerative colitis induced by combination therapy with PEG‐interferon alpha‐2b and ribavirin. Gut2006;55(11):1682‐3. ">Watanabe 2006</a>; <a href="./references#CD006790-bbs2-0058" title="SprengerR , SagmeisterM , OffnerF . Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis. Gut2005;54(3):438‐9. ">Sprenger 2005</a>; <a href="./references#CD006790-bbs2-0048" title="MavrogiannisC , PapanikolaouIS , ElefsiniotisIS , PsilopoulosDI , KaramerisA , KarvountzisG . Ulcerative colitis associated with interferon treatment for chronic hepatitis C. Journal of Hepatology2001;34(6):964‐5. ">Mavrogiannis 2001</a>). This would need to be studied by reviewing controlled clinical trials of type I IFNs in patients who are in remission. </p> <p>The results of this review should be interpreted with caution due to methodological concerns with the included studies. Even with data from the new included studies <a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> and <a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a>, there were only 362 patients in the pooled analysis for clinical remission and only 425 patients in the pooled analysis for clinical response. These sample sizes likely have suboptimal power to detect a difference in treatment effect should one exist. A sample size calculation was performed based on the magnitude of the observed treatment effect in the pooled analysis. Using the pooled proportion of patients achieving remission in the IFN group of 36.0% (87/242) and 30.0% (36/120) in the placebo group, α=0.05, β=0.8, a case sample size of 1954 individuals would be required assuming a 1:1 case:control ratio for two independent populations of UC patients and no cross‐overs. Furthermore, this estimate is conservative and does not take into account the potential yet substantial withdrawal rates demonstrated in the existing trials. </p> <p>There was clinical heterogeneity with variability in the isoform of IFN used (α versus β) and even in the studies using the same preparation of IFN‐β‐1a, there were marked differences in the dose used and the overall duration of treatment. It is possible that there may be isoform dependent and dose dependent effects. </p> <p>The use of different clinical indices for measuring UC activity limited comparison of treatment efficacy data. The use of standardised validated clinical activity indices should be emphasised. The use of the same endoscopic activity index permitted comparisons. However, the length of treatment and follow‐up may have been insufficient to allow for maximal endoscopic response. </p> <p>Based on the existing literature, the current evidence does not support the use of type I IFNs for induction of remission in patients with UC. Furthermore, there are concerns regarding the tolerability of this class of treatment. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD006790-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006790-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full#CD006790-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006790-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006790-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full#CD006790-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006790-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Type I Interferons versus placebo, outcome: 1.1 Remission (non pooled data)." data-id="CD006790-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Type I Interferons versus placebo, outcome: 1.1 Remission (non pooled data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full#CD006790-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006790-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Type I Interferons versus placebo, Outcome 1 Remission (non pooled data)." data-id="CD006790-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Type I Interferons versus placebo, Outcome 1 Remission (non pooled data).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#CD006790-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006790-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Type I Interferons versus placebo, Outcome 2 Remission (pooled data)." data-id="CD006790-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Type I Interferons versus placebo, Outcome 2 Remission (pooled data).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#CD006790-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006790-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Type I Interferons versus placebo, Outcome 3 Remission ‐ sensitivity analysis (IFN beta‐isoform)." data-id="CD006790-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Type I Interferons versus placebo, Outcome 3 Remission ‐ sensitivity analysis (IFN beta‐isoform). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#CD006790-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006790-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Type I Interferons versus placebo, Outcome 4 Remission ‐ sensitivity analysis (IFN alpha‐isoform)." data-id="CD006790-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Type I Interferons versus placebo, Outcome 4 Remission ‐ sensitivity analysis (IFN alpha‐isoform). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#CD006790-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006790-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Type I Interferons versus placebo, Outcome 5 Time to remission." data-id="CD006790-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Type I Interferons versus placebo, Outcome 5 Time to remission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#CD006790-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006790-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Type I Interferons versus placebo, Outcome 6 Clinical improvement." data-id="CD006790-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Type I Interferons versus placebo, Outcome 6 Clinical improvement.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#CD006790-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006790-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Type I Interferons versus placebo, Outcome 7 Clinical improvement ‐ sensitivity analysis published manuscripts only (fixed‐effect model)." data-id="CD006790-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Type I Interferons versus placebo, Outcome 7 Clinical improvement ‐ sensitivity analysis published manuscripts only (fixed‐effect model). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#CD006790-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006790-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Type I Interferons versus placebo, Outcome 8 Endoscopic activity index score." data-id="CD006790-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Type I Interferons versus placebo, Outcome 8 Endoscopic activity index score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#CD006790-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006790-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Type I Interferons versus placebo, Outcome 9 Serious adverse events." data-id="CD006790-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Type I Interferons versus placebo, Outcome 9 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#CD006790-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006790-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Type I Interferons versus placebo, Outcome 10 Serious adverse events ‐ sensitivity analysis published manuscripts only (random‐effects model)." data-id="CD006790-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Type I Interferons versus placebo, Outcome 10 Serious adverse events ‐ sensitivity analysis published manuscripts only (random‐effects model). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#CD006790-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006790-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Type I Interferons versus placebo, Outcome 11 Overall withdrawals." data-id="CD006790-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Type I Interferons versus placebo, Outcome 11 Overall withdrawals.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#CD006790-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006790-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Type I Interferons versus placebo, Outcome 12 Overall withdrawals ‐ sensitivity analysis published manuscripts only (fixed‐effect model)." data-id="CD006790-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Type I Interferons versus placebo, Outcome 12 Overall withdrawals ‐ sensitivity analysis published manuscripts only (fixed‐effect model). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#CD006790-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006790-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/urn:x-wiley:14651858:media:CD006790:CD006790-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_t/tCD006790-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Type I Interferons versus placebo, Outcome 13 Withdrawals due to adverse events." data-id="CD006790-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Type I Interferons versus placebo, Outcome 13 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#CD006790-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/media/CDSR/CD006790/image_n/nCD006790-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006790-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Type I Interferons compared to placebo for induction of remission in ulcerative colitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Type I Interferons compared to placebo for induction of remission in ulcerative colitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with induction of remission in ulcerative colitis<br/> <b>Settings:</b> Outpatient<br/> <b>Intervention:</b> Type I Interferons<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Type I Interferons</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Remission</b> <br/> Follow‐up: 8‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b> <br/> (252 to 474) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b> <br/> (0.84 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>362<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical improvement</b> <br/> Follow‐up: 8‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>478 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>554 per 1000</b> <br/> (459 to 669) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.16</b> <br/> (0.96 to 1.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>425<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> <br/> Follow‐up: 8‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>46 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>34 per 1000</b> <br/> (6 to 190) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.74</b> <br/> (0.13 to 4.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>468<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> <br/> Follow‐up: 8‐12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>20 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>62 per 1000</b> <br/> (21 to 186) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.16</b> <br/> (1.06 to 9.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>394<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk comes from control arm of study<br/> <sup>2</sup> Downgraded one level due to sparse data (123 events)<br/> <sup>3</sup> Dowgraded one level due to sparse data (226 events)<br/> <sup>4</sup> Downgraded two levels due to very sparse data (20 events)<br/> <sup>5</sup> Downgraded two levels due to very sparse data (21 events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Type I Interferons compared to placebo for induction of remission in ulcerative colitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full#CD006790-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006790-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overall withdrawals (%); Placebo versus Type I IFNs</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IFN Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High dose IFN</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low dose IFN</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006790-bbs2-0002" title="MannonP , FeaganB , XiY , McAllisterA , CataldiF . Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country‐enrollment site in a phase IIa study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S102‐3. MannonP , MinerP , LukasM , McAllisterA , CataldiF . Secondary efficacy analysis from a phase IIa multicenter study with interferon‐ß‐1a for induction of clinical response in active moderate to severe ulcerative colitis. American Journal of Gatroenterology2010;105:S468‐9. MannonP , PanaccioneR , MinerP , McAllisterA , O'GormanJ , CataldiF . Interferon‐ß‐1a in active moderate to severe ulcerative colitis: Efficacy and safety from a phase IIa multicenter study. American Journal of Gastroenterology2010;105:S446. MannonP , ReinischW , MinerP , McAllisterA , XiY , CataldiF . Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post‐hoc analysis in a phase 2a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S69‐70. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon‐ß‐1a in ulcerative colitis. Journal of Crohn's and Colitis2011;5(1):S94‐5. MannonP , ReinischW , MinerP , XiY , McAllisterA , CataldiF . Is there a difference between self‐assessed patient‐reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S84‐5. MinerP , LemboA , MannonP , XiY , McAllisterA , CataldiF . Stool frequency a subjective endpoint in ulcerative colitis and irritable bowel syndrome clinical trials. Comparison between stool frequency and mucosal healing from study with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S54‐5. MinerP , MannonP , RajagopalanK , McAllisterA , XiY , CataldiF . Improvement in work productivity: Analysis from a proof of concept in ulcerative colitis with Interferon‐B‐1a. Inflammatory Bowel Diseases2011;17:S55. MinerP , MannonP , ZakkoS , McAllisterA , O'GormanJ , CataldiF . Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon‐B‐1a in ulcerative colitis. Inflammatory Bowel Diseases2011;17:S36. MinerP , ZakkoS , McAllisterA , CataldiF . Safety analysis from a phase IIa multicenter study with interferon‐ß‐1a in active moderate to severe ulcerative colitis. American Journal of Gastroenterology2010;105:S433‐4. NCT00616434 . A multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and efficacy of Avonex® in subjects with moderate to severe ulcerative colitis. https://clinicaltrials.gov/ct2/show/study/NCT00616434 (accessed 8 August 2014). [NCT00616434] ReinischW , MannonP , MinerP , McAllisterA , XiY , CataldiF . Is elevated CRP a predictor of efficacy in ulcerative colitis? Post‐hoc analysis from a placebo‐controlled study with interferon‐ß‐1a. Journal of Crohn's and Colitis2011;5(1):S72‐3. ">Mannon 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006790-bbs2-0003" title="MuschE , AndusT , KruisW , RaedlerA , SpehlmannM , SchreiberS , et al. Interferon‐beta‐1a for the treatment of steroid‐refractory ulcerative colitis: a randomized, double‐blind, placebo‐controlled trial. Clinical Gastroenterology and Hepatology2005;3(6):581‐6. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. A phase II placebo‐controlled, randomized multicenter study to evaluate efficacy and safety of interferon beta‐1a in patients with ulcerative colitis. Gastroenterology2002;122(4 Suppl 1):A431. MuschE , RaedlerA , AndusT , KruisW , SchreiberS , LorenzA , et al. Results of a randomised, double‐blind, placebo‐controlled, multi‐centre, phase‐II study to test the effectivity and tolerance of Interferon‐beta‐1a (CHO‐beta) [rIFN‐beta‐1a] in patients with ulcerative colitis. Zeitschrift fur Gastroenterologie2002;40(8):705. ">Musch 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006790-bbs2-0004" title="NikolausS , RutgeertsP , FedorakR , SteinhartAH , WildGE , TheuerD , et al. Interferon beta‐1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut2003;52(9):1286‐90. NikolausS , RutgeertsP , FedorakRN , SteinhartH , WildGE , TheuerD , et al. Recombinant human interferon‐beta (IFNb‐1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology2001;120(5 Suppl 1):A454. ">Nikolaus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006790-bbs2-0005" title="Pena‐RossiC , SchreiberS , GolubovicG , Mertz‐NielsenA , PanesJ , RachmilewitzD , et al. Clinical trial: a multicentre, randomized, double‐blind, placebo‐controlled, dose‐finding, phase II study of subcutaneous interferon‐beta‐la in moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics2008;28(6):758‐67. ">Pena‐Rossi 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006790-bbs2-0006" title="TilgH , VogelsangH , LudwiczekO , LochsH , ColombelJF , RutgeertsP , et al. A randomized placebo‐controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology2003;124(4 Suppl 1):A62. TilgH , VogelsangH , LudwiczekO , LochsH , KaserA , ColombelJF , et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut2003;52(12):1728‐33. ">Tilg 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.6</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overall withdrawals (%); Placebo versus Type I IFNs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full#CD006790-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006790-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Comparative IFN‐b‐1a Doses used in the Nikolaus, Musch and Pena‐Rossi Trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose of IFN‐b‐1a</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Remission (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>%</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nikolaus 2003: Median treatment duration 35.5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88mcg t.i.w</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44mcg t.i.w.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22mcg t.i.w.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL (Nikolaus)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Musch 2005: Treatment duration: 56 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3MIU t.i.w. = 11mcg t.i.w.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1MIU t.i.w. = 3.7mcg t.i.w.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL (Musch)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>[12MIU = 44mcg] Reference: Antonetti 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pena‐Rossi 2008: Treatment duration: 56 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66mcg t.i.w.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44mcg t.i.w.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL (Pena‐Rossi)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.5</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Comparative IFN‐b‐1a Doses used in the Nikolaus, Musch and Pena‐Rossi Trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/full#CD006790-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006790-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Type I Interferons versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Remission (non pooled data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Tilg 0.5 mcg/kg PegIFN alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tilg 1.0 mcg/kg PegIFn alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Musch 1 MIU IFN‐b‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Musch 3 MIU IFN‐b‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Nikolaus IFN‐b ‐1a (Dose escalating study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Pena‐Rossi 44 mcg IFN‐b‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Pena‐Rossi 66 mcg IFN‐b‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Remission (pooled data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.84, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Remission ‐ sensitivity analysis (IFN beta‐isoform) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.84, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Remission ‐ sensitivity analysis (IFN alpha‐isoform) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Time to remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 1 MIU IFN b‐1‐a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐11.22, 7.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 3 MIU IFN b‐1‐a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.10 [‐12.71, 4.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Clinical improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.96, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Clinical improvement ‐ sensitivity analysis published manuscripts only (fixed‐effect model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.91, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Endoscopic activity index score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 1 MIU IFN b‐1‐a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐2.22, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 3 MIU IFN b‐1‐a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐0.91, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 0.5 mcg/kg IFN b‐1‐a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐2.94, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 1.0 mcg/kg IFN b‐1‐a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐2.14, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.13, 4.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Serious adverse events ‐ sensitivity analysis published manuscripts only (random‐effects model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.10, 10.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Overall withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.65, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Overall withdrawals ‐ sensitivity analysis published manuscripts only (fixed‐effect model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.66, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [1.06, 9.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Type I Interferons versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006790.pub3/references#CD006790-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006790.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006790-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006790-note-0005">فارسی</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006790\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006790\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006790\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006790\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006790\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7LavyS58&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006790.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006790.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006790.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006790.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006790.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720035200"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006790.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720035204"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006790.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df7526b3d9368',t:'MTc0MDcyMDAzNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 